< Back to previous page
Researcher
Johan Vansteenkiste
- Disciplines:Respiratory medicine
Affiliations
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) (Division)
Member
From1 Oct 1999 → 30 Sep 2022
Projects
1 - 3 of 3
- Refining the role of dual checkpoint inhibition in advanced lung cancer: a single-cell approachFrom5 Oct 2021 → TodayFunding: FWO Strategic Basic Research Grant
- A single-cell approach to identify biomarkers of efficacy and toxicity for immune checkpoint blockade in non-small cell lung cancer.From1 Aug 2019 → 1 Aug 2023Funding: FWO Strategic Basic Research Grant, Foundations, funds and other with scientific goal
- Unraveling the common genetic basis for COPD, emphysema and lung cancer.From1 Aug 2010 → 16 Dec 2015Funding: Private funding of national origin - undefined, FWO fellowships
Publications
1 - 10 of 277
- Single-cell phenotyping to unravel the immunopathology of immune checkpoint inhibitor-related pneumonitis. Lessons learnt from the COVID-19 pandemic(2023)
Authors: Pierre Van Mol, Els Wauters, Johan Vansteenkiste, Diether Lambrechts
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.(2023)
Authors: Johan Vansteenkiste
Pages: 2458 - 2466 - Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors(2023)
Authors: Johan Vansteenkiste
Pages: 142 - 151 - Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer (Reprinted from vol 21, pg 2237-2246, 2003)(2023)
Authors: Johan Vansteenkiste
Pages: 1162 - 1171 - A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.(2023)
Authors: Johan Vansteenkiste
Pages: 61 - 75 - Treatment of unresectable stage III NSCLC: Real world cohort study and literature review.(2023)
Authors: Maarten Lambrecht, Christophe Dooms, Kristiaan Nackaerts, Johan Vansteenkiste, Els Wauters
Pages: 100727 - Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis(2022)
Authors: Pierre Van Mol, Sam Vanmassenhove, Christophe Dooms, Dries Testelmans, Kristiaan Nackaerts, Johan Vansteenkiste, Robin Vos, Stephanie Humblet-Baron, Diether Lambrechts, Els Wauters
- Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches(2022)
Authors: Pierre Van Mol, Els Wauters, Johan Vansteenkiste
Pages: 893 - 908 - Capmatinib vs docetaxel as second- or third-line therapy in patients with locally advanced or metastatic METex14-mutated NSCLC: The GeoMETry-III trial(2022)
Authors: Johan Vansteenkiste
- A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer(2022)
Authors: Johan Vansteenkiste
Pages: 773 - 776